Marcia L. Stefanick

Marcia L. Stefanick

Auto-generated profile, based on publicly available information

Marcia L. Stefanick

Stanford University

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2006 in JAMA
Verified
Journal Article
Open access
PDF file
MSMarcia L. Stefanick
Marcia L. Stefanick
GAGarnet L. Anderson
Garnet L. Anderson
KMKaren L. Margolis
Karen L. Margolis
SHSusan L. Hendrix
Susan L. Hendrix
RRRebecca J. Rodabough
Rebecca J. Rodabough
FIfor the WHI Investigators
for the WHI Investigators
In the Women's Health Initiative (WHI) randomized Estrogen plus Progestin (E + P) trial in postmenopausal women, oral conjugated equine estrogens (CEE) combined with medroxyprogesterone acetate produced more health risks than benefits,1 including a higher incidence of invasive breast cancers, which were diagnosed at a more advanced stage, and a substantially greater proportion of abnormal mammograms compared with placebo.2 The parallel WHI Estrogen-Alone trial, which randomized women with prior hysterectomy to CEE only or placebo, was stopped early based on available data representing an average of 6.8 years of follow-up because of increased stroke incidence and no reduction in risk of coronary heart disease.3 In contrast to substantial epidemiological evidence associating exogenous estrogens with increased breast cancer incidence,4-9 preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports. The completed trial results reported herein include all events occurring prior to the stopping of the intervention and unblinding. Biologically plausible explanations for the possibility of decreased incidence of breast cancer with CEE are considered and examined in exploratory analyses, including interactions of treatment assignment with baseline risk factors.

22 February 2021 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
MNMathias W. Nielsen
Mathias W. Nielsen
MSMarcia L. Stefanick
Marcia L. Stefanick
DPDiana Peragine
Diana Peragine
Torsten B. NeilandsTorsten B. Neilands
Torsten B. Neilands
JIJohn P. A. Ioannidis
John P. A. Ioannidis
LSLonda Schiebinger
Londa Schiebinger
Background: In this paper, we argue for Gender as a Sociocultural Variable (GASV) as a complement to Sex as a Biological Variable (SABV). Sex (biology) and gender (sociocultural behaviors and attitudes) interact to influence health and disease processes across the lifespan—which is currently playing out in the COVID-19 pandemic. This study develops a gender assessment tool—the Stanford Gender-Related Variables for Health Research—for use in clinical and population research, including large-scale health surveys involving diverse Western populations. While analyzing sex as a biological variable is widely mandated, gender as a sociocultural variable is not, largely because the field lacks quantitative tools for analyzing the influence of gender on health outcomes.Methods: We conducted a comprehensive review of English-language measures of gender from 1975 to 2015 to identify variables across three domains: gender norms, gender-related traits, and gender relations. This yielded 11 variables tested with 44 items in three US cross-sectional survey populations: two internet-based (N= 2051;N= 2135) and a patient-research registry (N= 489), conducted between May 2017 and January 2018.Results: Exploratory and confirmatory factor analyses reduced 11 constructs to 7 gender-related variables: caregiver strain, work strain, independence, risk-taking, emotional intelligence, social support, and discrimination. Regression analyses, adjusted for age, ethnicity, income, education, sex assigned at birth, and self-reported gender identity, identified associations between these gender-related variables and self-rated general health, physical and mental health, and health-risk behaviors.Conclusion: Our new instrument represents an important step toward developing more comprehensive and precise survey-based measures of gender in relation to health. Our questionnaire is designed to shed light on how specific gender-related behaviors and attitudes contribute to health and disease processes, irrespective of—or in addition to—biological sex and self-reported gender identity. Use of these gender-related variables in experimental studies, such as clinical trials, may also help us understand if gender factors play an important role as treatment-effect modifiers and would thus need to be further considered in treatment decision-making.

12 August 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
MEMark A. Espeland
Mark A. Espeland
SSSally A. Shumaker
Sally A. Shumaker
ILIris Leng
Iris Leng
JMJoAnn E. Manson
JoAnn E. Manson
CBCandice M. Brown
Candice M. Brown
SRSusan M. Resnick
Susan M. Resnick
The Women’s Health Initiative Memory Study (WHIMS) demonstrated that postmenopausal hormone therapy with conjugated equine estrogens (CEEs), when prescribed to women 65 years and older, produced deficits in global and domain-specific cognitive functioning.1-3 On average, these were small; however, deficits persisted for years after cessation of hormone therapy.3 They occurred in conjunction with decreases in brain volume linked to increased incidence of cognitive impairment.4,5


1 April 2011 in Menopause
Verified
Journal Article
Closed access
STSandra A. Tsai
Sandra A. Tsai
MSMarcia L. Stefanick
Marcia L. Stefanick
RSRandall Stafford
Randall Stafford
Objective: The aim of this study was to evaluate recent trends and the adoption of practice recommendations for menopausal hormone therapy (MHT) use from 2001 to 2009 by formulation, dose, woman's age, and characteristics of physicians reporting MHT visits. Methods: The IMS Health (Plymouth Meeting PA) National Disease and Therapeutic Index physician survey data from 2001 to 2009 were analyzed for visits in which MHT use was reported by US office-based physicians. Estimated national volume of visits for which MHT use was reported. Results: MHT use declined each year since 2002. Systemic MHT use fell from 16.3 million (M) visits in 2001 to 6.1 M visits in 2009. Declines were greatest for women 60 years or older (64%) but were also substantial for women younger than 50 years (59%) and women 50 to 59 years old (60%). Women 60 years or older accounted for 37% of MHT use. Lower dose product use increased modestly, from 0.7 M (2001) to 1.3 M (2009), as did vaginal MHT use, from 1.8 M (2001) to 2.4 M (2009). Declines in continuing systemic MHT use (65%) were greater than for newly initiated MHT use (51%). Compared with other physicians, obstetrician/gynecologists changed their practices less, thereby increasing their overall share of total MHT visits from 72% (2001) to 82% (2009). Conclusions: Total MHT use has steadily declined. Increased use of lower dose and vaginal products reflects clinical recommendations. Uptake of these products, however, has been modest, and substantial use of MHT continues in older women.

14 February 2017 in BMC Public Health
Verified
Journal Article
Open access
PDF file
ALAndrea Z. LaCroix
Andrea Z. LaCroix
EREileen Rillamas-Sun
Eileen Rillamas-Sun
DBDavid Buchner
David Buchner
KEKelly Evenson
Kelly Evenson
CDChongzhi Di
Chongzhi Di
AHAmy H. Herring
Amy H. Herring
Limited evidence exists to inform physical activity (PA) and sedentary behavior guidelines for older people, especially women. Rigorous evidence on the amounts, intensities, and movement patterns associated with better health in later life is needed. The Objective PA and Cardiovascular Health (OPACH) Study is an ancillary study to the Women’s Health Initiative (WHI) Program that examines associations of accelerometer-assessed PA and sedentary behavior with cardiovascular and fall events. Between 2012 and 2014, 7048 women aged 63–99 were provided with an ActiGraph GT3X+ (Pensacola, Florida) triaxial accelerometer, a sleep log, and an OPACH PA Questionnaire; 6489 have accelerometer data. Most women were in their 70s (40%) or 80s (46%), while approximately 10% were in their 60s and 4% were age 90 years or older. Non-Hispanic Black or Hispanic/Latina women comprise half of the cohort. Follow-up includes 1-year of falls surveillance with monthly calendars and telephone interviews of fallers, and annual follow-up for outcomes with adjudication of incident cardiovascular disease (CVD) events through 2020. Over 63,600 months of calendar pages were returned by 5,776 women, who reported 5,980 falls. Telephone interviews were completed for 1,492 women to ascertain the circumstances, injuries and medical care associated with falling. The dataset contains extensive information on phenotypes related to healthy aging, including inflammatory and CVD biomarkers, breast and colon cancer, hip and other fractures, diabetes, and physical disability. This paper describes the study design, methods, and baseline data for a diverse cohort of postmenopausal women who wore accelerometers under free-living conditions as part of the OPACH Study. By using accelerometers to collect more precise and complete data on PA and sedentary behavior in a large cohort of older women, this study will contribute crucial new evidence about how much, how vigorous, and what patterns of PA are necessary to maintain optimal cardiovascular health and to avoid falls in later life. ClinicalTrials.gov identifier NCT00000611 . Registered 27 October 1999.